CDXS CODEXIS, INC.
Industrial Organic Chemicals · Nasdaq · SEC CIK 1200375 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY66.9%
TTM net income YoY69.9%
TTM EPS YoY75.3%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR—
Margins
Gross margin86.8%
Operating margin-18.3%
Net margin-21.8%
FCF margin-13.7%
EBITDA margin-12.6%
Returns
ROE-42.9%
ROA-14.3%
ROIC (approx.)-22.0%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets64.5%
Debt / equity0.81x
Current ratio2.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio-6.5%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $19.26M | $14.91M | $15.25M | $38.91M | $8.60M | $15.33M | $7.54M | $21.46M |
| Cost of revenue | $4.01M | $3.51M | $2.06M | $2.04M | $2.46M | $2.10M | $2.73M | $3.65M |
| Gross profit | $15.25M | $11.40M | $13.18M | $36.87M | $6.14M | $13.23M | $4.81M | $17.81M |
| R&D expense | $12.59M | $11.71M | $11.45M | $11.72M | $13.87M | $13.78M | $12.94M | $12.10M |
| SG&A expense | $10.10M | $10.93M | $9.78M | $11.19M | $11.22M | $12.32M | $12.36M | $13.05M |
| Operating income | -$7.44M | -$11.23M | -$8.04M | $10.56M | -$18.95M | -$12.86M | -$20.49M | -$7.34M |
| Pretax income | -$8.12M | -$11.99M | -$8.67M | $9.62M | -$19.61M | -$13.26M | -$20.68M | -$10.37M |
| Income tax | $9,000 | $10,000 | $36,000 | $18,000 | $8,000 | $10,000 | $11,000 | $3,000 |
| Net income | -$8.13M | -$12.01M | -$8.70M | $9.60M | -$19.61M | -$13.27M | -$20.69M | -$10.38M |
| EBITDA | -$6.30M | -$10.03M | -$6.76M | $11.92M | -$17.63M | -$11.56M | -$19.29M | -$6.13M |
| EPS (basic) | -0.08 | -0.13 | -0.10 | — | -0.22 | -0.16 | -0.25 | — |
| EPS (diluted) | -0.08 | -0.13 | -0.10 | — | -0.22 | -0.16 | -0.25 | — |
| Weighted avg. shares (diluted) | 107.26M | 91.05M | 90.77M | — | 90.25M | 85.39M | 82.41M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $29.21M | $27.17M | $36.57M | $50.79M | $25.35M | $26.76M | $18.32M | $20.83M |
| Short-term investments | $43.45M | $27.75M | $28.57M | $27.42M | $33.35M | $39.57M | $41.50M | $54.19M |
| Inventory | $2.10M | $1.60M | $2.00M | $1.82M | $1.94M | $1.95M | $1.78M | $1.80M |
| Current assets | $95.77M | $71.92M | $79.65M | $96.82M | $76.19M | $88.73M | $77.81M | $98.77M |
| PP&E, net | $13.33M | $11.91M | $12.59M | $13.02M | $14.01M | $14.98M | $15.80M | $14.20M |
| Goodwill | $2.46M | $2.46M | $2.46M | $2.46M | $2.46M | $2.46M | $2.46M | $2.46M |
| Total assets | $144.22M | $120.06M | $129.37M | $147.80M | $123.96M | $138.25M | $128.89M | $149.01M |
| Current liabilities | $34.09M | $23.51M | $14.85M | $25.32M | $18.48M | $15.24M | $20.90M | $23.65M |
| Short-term debt | $11.79M | $7.06M | — | $0 | — | — | — | — |
| Long-term debt | $29.48M | $33.82M | $40.48M | $40.10M | $39.73M | $39.37M | $29.19M | $28.91M |
| Total debt | $41.28M | $40.88M | $40.48M | $40.10M | $39.73M | $39.37M | $29.19M | $28.91M |
| Total liabilities | $92.98M | $87.10M | $86.14M | $97.27M | $85.42M | $82.61M | $79.26M | $82.08M |
| Shareholders' equity | $51.24M | $32.96M | $43.23M | $50.53M | $38.54M | $55.63M | $49.63M | $66.93M |
| Net debt | $12.06M | $13.70M | $3.91M | -$10.69M | $14.38M | $12.61M | $10.87M | $8.08M |
| Shares outstanding | 109.52M | 91.39M | 90.89M | 90.48M | 90.28M | 90.25M | 82.84M | 81.85M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.77M | -$9.64M | -$13.15M | $20.09M | -$7.70M | -$17.97M | -$13.80M | -$16.47M |
| Capital expenditure | $74,000 | $898,000 | $176,000 | $520,000 | $182,000 | $2.51M | $1.25M | $1.77M |
| Free cash flow | -$7.84M | -$10.54M | -$13.33M | $19.57M | -$7.88M | -$20.48M | -$15.05M | -$18.24M |
| Investing cash flow | -$15.61M | $175,000 | -$1.11M | $5.71M | $6.39M | -$367,000 | $11.77M | -$2.86M |
| Financing cash flow | $25.00M | $66,000 | -$14,000 | $180,000 | -$111,000 | $26.77M | $1.08M | $1.13M |
| Depreciation & amortization | $1.14M | $1.20M | $1.29M | $1.36M | $1.32M | $1.30M | $1.20M | $1.21M |
| Stock-based compensation | $1.55M | $1.58M | $1.43M | $2.20M | $2.51M | $2.53M | $2.38M | $2.53M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.